Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15914393 | 1.00 | TFPI2 (0.37) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL458523 | 1.00 | TFPI2 (0.37) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL15914391 | 1.00 | TFPI2 (0.37) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL15914392 | 1.00 | TFPI2 (0.37) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL468430 | 0.87 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL20679256 | 0.87 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL9978357 | 0.87 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL15378131 | 0.87 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL468523 | 0.87 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 | |
| SCHEMBL844707 | 0.87 | TFPI2 (0.41) | TFPI2LMNAKDM4EGMNNPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4122935-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11548901-B2 | Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3608325-B1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20210053988-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-10689399-B2 | Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3608325-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3067358-B1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190092787-A1 | SUBSTITUTED 2,3,4,5,7,9,13,13A-OCTAHYDRO-1,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[1,3]DIAZEPINES AND METHODS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
| US-10035809-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170260204-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9732092-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9663528-B2 | Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170057976-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-3067358-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160176885-A1 | SUBSTITUTED 1,2,3,4,6,8,12,12a-OCTAHYDRO-1,4-METHANODIPYRIDO[1,2-a:1',2'-d]PYRAZINES AND METHODS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-2822954-B1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-9216996-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections | GILEAD SCIENCES, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| US-8158658-B2 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NORTHWESTERN UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176885-A1 | SUBSTITUTED 1,2,3,4,6,8,12,12a-OCTAHYDRO-1,4-METHANODIPYRIDO[1,2-a:1',2'-d]PYRAZINES AND METHODS FOR TREATING VIRAL INFECTIONS | PYM1, ZC3HAV1, ZYX | TFPI2 3705/4885LMNA 3159/4885KDM4E 2136/4885 |
| US-20190092787-A1 | SUBSTITUTED 2,3,4,5,7,9,13,13A-OCTAHYDRO-1,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[1,3]DIAZEPINES AND METHODS FOR TREATING VIRAL INFECTIONS | ZC3HAV1, PYM1, CCR5 | TFPI2 4318/4885LMNA 2522/4885KDM4E 1069/4885 |
| US-10689399-B2 | Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections | PYM1, ZYX, XDH | TFPI2 4659/4885LMNA 3301/4885KDM4E 1600/4885 |
| US-10035809-B2 | Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections | PYM1, ZC3HAV1, CD4 | TFPI2 4391/4885LMNA 2194/4885KDM4E 1609/4885 |
| US-20210053988-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | TFPI2 3193/4885LMNA 3835/4885KDM4E 400/4885 |
| US-20140221356-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | TFPI2 3193/4885LMNA 3835/4885KDM4E 400/4885 |
| US-20170057976-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | TFPI2 3193/4885LMNA 3835/4885KDM4E 400/4885 |
| US-20170260204-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZC3HAV1, PYM1, ZC3HAV1L | TFPI2 3193/4885LMNA 3835/4885KDM4E 400/4885 |
| US-11548901-B2 | Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections | PYM1, XDH, CYP2S1 | TFPI2 3971/4885LMNA 3018/4885KDM4E 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.